Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38, Semaglutide is approved for type 2 diabetes and chronic weight management, significantly lowering HbA1c and body weight by modulating incretin pathways232480.
While FOXO4-DRI works as a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38, Semaglutide is a modified GLP-1(7–37) analog with three key changes—Ala8→Aib, Lys26 acylated with a C18 fatty diacid, and Lys34→Arg—resulting in a long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite23647480.
FOXO4-DRI
FOXO4
Semaglutide
GCG
FOXO4-DRI and Semaglutide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: FOXO4-DRI is more often discussed in the realm of Aging and longevity, whereas Semaglutide is more often associated with the realm of Metabolic and endocrine and Cardiovascular health. Their biological logic is quite different: FOXO4-DRI is a protein interaction inhibitor, whereas Semaglutide is a receptor agonist and a hormone analog. FOXO4-DRI has a more synthetic design origin, while Semaglutide is closer to synthetic analog background and their development context also differs, with FOXO4-DRI in Preclinical development while Semaglutide is approved. FOXO4-DRI takes the form of a linear peptide, whereas Semaglutide is closer to a peptide conjugate, FOXO4-DRI carries retro-inverso isomerization features, while Semaglutide instead reflects lipidation changes; while their sequence patterns also diverge, with FOXO4-DRI showing protein-mimetic sequence features and Semaglutide showing alpha-helical domain features.